Skip to main content
Stills pts w/ remission on Tocilizumab who stop TCZ, 50% will relapse in 1 yr. Lower relapse rate w/ longer TCZ use w/ p

Dr. John Cush RheumNow

2 years 5 months ago
Stills pts w/ remission on Tocilizumab who stop TCZ, 50% will relapse in 1 yr. Lower relapse rate w/ longer TCZ use w/ prednisolone lowering. 38/48 AOSD Rx w/ TCZ were in remission after 6 mos. & 12 D/C TCZ - half flared after mean of 5.5 mos.https://t.co/L9XbUX8lXn https://t.co/Z4oixQR2oX
Infection and Rituximab-linked Immunoglobulin Deficiency

A recent cohort analysis suggests that RTX-induced Ig deficie

Dr. John Cush RheumNow

2 years 5 months ago
Infection and Rituximab-linked Immunoglobulin Deficiency A recent cohort analysis suggests that RTX-induced Ig deficiency was not associated with an increased risk of severe infection in IMID patients. https://t.co/mcEc0FpdpR https://t.co/S2vAXSWlso
Case of Delayed Rheum Diagnosis
The Washington Post recently published a case titled, "Medical Mysteries: A rolled ankle

Dr. John Cush RheumNow

2 years 5 months ago
Case of Delayed Rheum Diagnosis The Washington Post recently published a case titled, "Medical Mysteries: A rolled ankle set this runner down a painful path", which tells the tale of how/why rheums are often not consulted or consulted too late. https://t.co/rusIwlELHu https://t.co/5ePDh4aFDY
929 Sjogrens pts from 2 French cohorts subdivided into 3 Groups:
1. BALS: Hi B-cell activity, low Sxs (Dz activity wors

Dr. John Cush RheumNow

2 years 5 months ago
929 Sjogrens pts from 2 French cohorts subdivided into 3 Groups: 1. BALS: Hi B-cell activity, low Sxs (Dz activity worsened w/ time) 2. HSA: Hi systemic Dz 3. LSAHS: low systemic Dz, Hi Sxs Lymphomas in 3-4% BALS & HSA https://t.co/xI8qjLO8YQ https://t.co/Z2JBuKSUhi
French claims data study of Serious infections in 12K #PsA pts Rx w/ biologics (2015-2020) found 367 (3%) w/serious infx

Dr. John Cush RheumNow

2 years 5 months ago
French claims data study of Serious infections in 12K #PsA pts Rx w/ biologics (2015-2020) found 367 (3%) w/serious infxn (17/1000Pys). Compared to adalimumab, a signif. lower SIE risk was seen w/ ETN (HR 0.72), & ustekinumab (HR 0.57) https://t.co/oVomnKuYGJ https://t.co/y5DQatFoCa
Series of Chronic Cutaneous Lupus responding to anifrolumab. 6 pts (4 DLE, 2 CCLE) betw 37-66 yrs old w/ Dz duration 10.

Dr. John Cush RheumNow

2 years 5 months ago
Series of Chronic Cutaneous Lupus responding to anifrolumab. 6 pts (4 DLE, 2 CCLE) betw 37-66 yrs old w/ Dz duration 10.5 yrs, 4 w/ SLE, all refractory to multiple therapies Rx w/ ANIF w/ Skin benefit. 1 developed herpes, 1 had worsening of nephritis https://t.co/XF8uW5xR66 https://t.co/hIJi94uRvr
An expert panel has published their consensus guidelines for the management of psoriatic arthritis (PsA) and it's comorbidities in the journal Rheumatology. 
Frequent musculoskeletal pain is linked with an increased risk of exiting work and retiring earlier, according to a new study published in the journal PLOS ONE.
We're gearing up for Tuesday Night Rheumatology all April long. Register today!

Our first TNR takes place 4/2 at 6:30p

Dr. John Cush RheumNow

2 years 5 months ago
We're gearing up for Tuesday Night Rheumatology all April long. Register today! Our first TNR takes place 4/2 at 6:30pm ET and will focus on Success in Rheumatoid Arthritis. https://t.co/TTMK07Bf7u https://t.co/lSxmfXI4sD
Top 10 Pharma R&D Budgets in 2023

Pharma budgets have undergone significant changes since COVID. This year Merck &

Dr. John Cush RheumNow

2 years 5 months ago
Top 10 Pharma R&D Budgets in 2023 Pharma budgets have undergone significant changes since COVID. This year Merck & Co. has knocked Roche from previous years of leading in R&D budgets and investments. https://t.co/xx0eKgXaiQ https://t.co/tMrFlatoMk
Insights on Postinfectious ME/CFS

JAMA has reviewed a recent Nature paper wherein an NIH led team of multidisciplinary

Dr. John Cush RheumNow

2 years 5 months ago
Insights on Postinfectious ME/CFS JAMA has reviewed a recent Nature paper wherein an NIH led team of multidisciplinary experts performed an inpatient study of postinfectious ME/CFS patients. https://t.co/3NiJCqZVy0 https://t.co/GAoBW9U1DW
91 #SLE pts w/ no baseline synovitis, underwent Ultrasound exams. 10 yrs later, 31 had clinical progression of arthritis

Dr. John Cush RheumNow

2 years 5 months ago
91 #SLE pts w/ no baseline synovitis, underwent Ultrasound exams. 10 yrs later, 31 had clinical progression of arthritis. Pts w/ progression, 75% had baseline subclinical synovitis on US vs without progression 77% did NOT have an abnormal US at baseline https://t.co/MN9wkNgsQV https://t.co/ozgvjFI531
A minority of immune-mediated inflammatory disease (IMID) patients treated with rituximab (RTX) are expected to develop and depressed immunoglobulin (Ig) levels.  A recent cohort analysis suggests that RTX-induced Ig deficiency was not associated with an increased risk of severe infection in IMID patients.
The Washington Post recently published a "medical mystery" case titled, "Medical Mysteries: A rolled ankle set this runner down a painful path", which tells the tale of how and why rheumatologists are often not consulted or are consulted too late.
Biden signs executive order on womens health research ($200 million to NIH interdisc. women res), focus on:
- integrate

Dr. John Cush RheumNow

2 years 5 months ago
Biden signs executive order on womens health research ($200 million to NIH interdisc. women res), focus on: - integrate Women’s Health Across Federal Research prgs - fund Research on Women’s Midlife Health - double funding Office Womens Health Research https://t.co/NKtI5iFKeb https://t.co/G5T0YEdEkO
×